Could a simple drug addition ease knee replacement pain?
NCT ID NCT07176065
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 29 times
Summary
This study tests whether adding dexmedetomidine to a standard painkiller (ropivacaine) can improve pain control after total knee replacement. Many patients still have moderate to severe pain after surgery despite current treatments. Sixty adults having knee replacement will be randomly assigned to receive either the standard painkiller alone or with dexmedetomidine. Researchers will track pain scores, opioid use, and recovery for 24 hours after surgery to see if the combination is more effective and safer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTOPERATIVE PAIN MANAGEMENT IN TOTAL KNEE ARTHROPLASTY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universiti Malaya Medical Centre
Kuala Lumpur, Kuala Lumpur, 59100, Malaysia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.